Pier 88 Investment Partners’s Krystal Biotech KRYS Stock Holding History

Pier 88 Investment Partners’s Portfolio KRYS Stock Details KRYS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$904K	Sell	3,500 -470	-12%	-$125K	0.23%	54
2025 Q4	$979K	Buy	3,970 +150	+4%	+$31.6K	0.22%	55
2025 Q3	$674K	Hold	3,820	–	–	0.13%	73
2025 Q2	$525K	Sell	3,820 -610	-14%	-$89.6K	0.1%	87
2025 Q1	$799K	Buy	4,430 +680	+18%	+$114K	0.15%	65
2024 Q4	$587K	Buy	3,750 +220	+6%	+$39K	0.12%	69
2024 Q3	$643K	Buy	3,530 +170	+5%	+$32.8K	0.14%	64
2024 Q2	$617K	Buy	3,360 +2,190	+187%	+$368K	0.14%	74
2024 Q1	$208K	Hold	1,170	–	–	0.05%	89
2023 Q4	$145K	Buy	+1,170	New	+$130K	0.04%	86

Other funds holding KRYS

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Pier 88 Investment Partners's KRYS Position: Q1 2026 in Review

Pier 88 Investment Partners reduced its Krystal Biotech (KRYS) stake by 12% in Q1 2026, selling an estimated $125K and leaving 3,500 shares worth $904K. The position accounts for 0.23% of the portfolio, ranked #54.

Pier 88 Investment Partners first reported a position in KRYS in Q4 2023 and has held it in 10 quarters since. The position peaked at $979K in Q4 2025. 367 funds tracked by Wall St. Rank hold KRYS as of Q1 2026.

Pier 88 Investment Partners held 3,500 shares of Krystal Biotech worth $904K as of Q1 2026.
Pier 88 Investment Partners sold 470 Krystal Biotech shares in Q1 2026, an estimated $125K.
Krystal Biotech made up 0.23% of Pier 88 Investment Partners's portfolio in Q1 2026, its #54 holding.
Pier 88 Investment Partners first reported a position in Krystal Biotech in Q4 2023 and has held it in 10 quarters since.
Pier 88 Investment Partners's Krystal Biotech position peaked at $979K in Q4 2025.
367 funds tracked by Wall St. Rank held Krystal Biotech as of Q1 2026.

Based on Pier 88 Investment Partners's 13F filing for Q1 2026, filed 11 May 2026.